peptideInjectableNot FDA-approvedResearch chemical
KPVBenefits, Dosage & Interactions
Also known as: Lysine-Proline-Valine
KPV, or Lysine-Proline-Valine, is a naturally occurring tri-peptide derived from the alpha-melanocyte-stimulating hormone (alpha-MSH). It is a synthetic analog of the C-terminal amino acid sequence of alpha-MSH, which is known for its immunomodulatory and anti-inflammatory effects. Research on KPV focuses on tissue recovery.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
Not established in humans
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Worked example: a 5 mg vial reconstituted with 2 ml of bacteriostatic water gives 2.5 mg/ml, so a 250 mcg amount measures 10 units on a U-100 syringe. Open this in the reconstitution calculator.
Reported for KPV in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the KPV entry is written from. Each number matches an inline marker above.
- [1]Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel diseaseKannengiesser K, Maaser C, Heidemann J, et al. · Inflammatory Bowel Diseases · 2008 · Peer-reviewed · PMID 18092346
- [2]Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative ColitisXiao B, Xu Z, Viennois E, et al. · Molecular Therapy · 2017 · Peer-reviewed · PMID 28143741
How to track KPV doses
KPV is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so KPV is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when KPV comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
Review KPV alongside your logged metrics and any relevant blood work every few weeks before changing the dose, so the change is a response to data rather than to a good or bad day.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document KPV dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is KPV studied for?
What is KPV?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
KPV, or Lysine-Proline-Valine, is a naturally occurring tri-peptide derived from the alpha-melanocyte-stimulating hormone (alpha-MSH). It is a synthetic analog of the C-terminal amino acid sequence of alpha-MSH, which is known for its immunomodulatory and anti-inflammatory effects. While alpha-MSH is a complex hormone with a wide range of biological activities, KPV specifically targets its anti-inflammatory mechanisms.
Research on KPV has primarily focused on its potential therapeutic applications in inflammatory conditions, particularly those affecting the skin and gastrointestinal tract. It has been investigated for its ability to reduce inflammation, promote wound healing, and modulate immune responses in various in vitro and in vivo models. The peptide is typically administered topically or via injection in research settings, depending on the target tissue.
As a peptide, KPV is generally considered to have a relatively short half-life and is not regulated as a controlled substance. Its use is predominantly in research contexts, and it is not an FDA-approved drug for human use. Due to its short half-life of approximately 1 hour, frequent administration might be necessary in research protocols to maintain consistent levels.
What does the research say about KPV?
Tap a section to expand.
KPV exerts its anti-inflammatory and immunomodulatory effects through several proposed mechanisms, primarily by interacting with cellular pathways involved in inflammation. The core mechanism involves its ability to inhibit the activation of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway. NF-κB is a protein complex that controls transcription of DNA, cytokine production, and cell survival. It plays a key role in regulating the immune response to infection and also in inflammatory processes. By inhibiting NF-κB, KPV can reduce the expression of pro-inflammatory cytokines such as TNF-alpha (tumor necrosis factor-alpha) and IL-6 (interleukin-6), as well as metalloproteinases and adhesion molecules that contribute to inflammation (PubChem).
Additionally, KPV has been shown to modulate the activity of specific enzymes involved in inflammation. For instance, in some studies, KPV has been reported to inhibit the activity of protein kinase C (PKC), a family of enzymes that phosphorylate proteins and play a role in various cellular signaling pathways, including those involved in inflammation and cell proliferation. By inhibiting PKC, KPV can further dampen inflammatory responses.
Beyond direct anti-inflammatory pathways, KPV may also contribute to tissue repair and regeneration. Research suggests it can influence cell migration and proliferation, which are crucial processes for wound healing. Its effects on cellular signaling indicate a broad modulatory capacity over inflammatory and regenerative responses at the cellular level.
Source for this section: Sources for How does KPV work?: Jumps to this entry in the sources and references list at the end of the page.
KPV has been studied for a range of potential benefits, primarily centered on its anti-inflammatory and tissue-healing properties:
* **Reduction of Inflammation:** The primary benefit investigated is its ability to reduce inflammation. Studies in animal models of inflammatory bowel disease (IBD) have shown that KPV can decrease colonic inflammation, reduce tissue damage, and improve disease symptoms. Similarly, in dermatological contexts, it has been shown to reduce inflammation in skin models (PubChem).
* **Promotion of Wound Healing:** KPV has demonstrated potential in accelerating wound healing. Research indicates it can promote skin cell migration and proliferation (fibroblasts and keratinocytes), which are essential for wound closure and tissue repair. This effect has been observed in various wound models, including thermal burns and excisional wounds (PubChem).
* **Modulation of Immune Response:** By influencing cytokine production and NF-κB signaling, KPV can modulate immune responses, shifting them away from pro-inflammatory states. This immunomodulatory effect may be beneficial in conditions where an overactive or dysregulated immune response contributes to pathology.
* **Potential in Dermatological Conditions:** Given its effects on skin inflammation and wound healing, KPV is being explored for its potential use in conditions like psoriasis, eczema, and other inflammatory skin disorders. Its topical application could offer a targeted approach to managing these conditions (PubChem).
* **Potential in Gastrointestinal Conditions:** Research into KPV's impact on gut inflammation suggests it may have therapeutic potential for inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, where inflammation of the digestive tract is a key feature.
It is important to note that these benefits are primarily derived from preclinical studies (in vitro and animal models), and extensive human clinical trials are needed to confirm efficacy and safety before KPV can be considered a therapeutic agent for any condition.
Evidence for KPV's effects largely stems from in vitro studies and animal models. For example, research published in peer-reviewed journals such as *Peptides* and *Molecular Medicine* has demonstrated KPV's anti-inflammatory properties in various models. A study described in PubChem highlighted KPV's ability to inhibit NF-κB activation and reduce the production of pro-inflammatory cytokines in human keratinocytes and colonic epithelial cells.
In animal models of inflammatory bowel disease (IBD), KPV administration has been shown to reduce colitis severity, ameliorate mucosal damage, and decrease the expression of inflammatory markers. For instance, studies using dextran sulfate sodium (DSS)-induced colitis models in mice have reported protective effects of KPV on the intestinal barrier and a reduction in leukocyte infiltration.
Dermatological research has also provided evidence. In models of skin inflammation, such as those induced by UV radiation or chemical irritants, topical KPV has been observed to reduce erythema (redness) and inflammatory cell infiltration, suggesting its potential for soothing irritated skin.
While these studies provide a strong foundational understanding of KPV's mechanisms and potential, human clinical data are scarce. The findings, while promising, are preliminary and do not yet support KPV as an approved treatment for any human condition. Further research, particularly well-designed human clinical trials, is required to validate these preclinical observations and establish safe and effective applications.
As KPV is primarily a research compound, comprehensive data on side effects in humans are limited. Based on preclinical studies and the nature of peptides, potential side effects could include:
* **Local irritation:** If administered topically or via injection, irritation, redness, swelling, or discomfort at the application site may occur.
* **Allergic reactions:** As with any peptide or protein, there is a theoretical risk of allergic or hypersensitivity reactions, although these are not commonly reported in the limited literature.
* **Systemic effects:** While KPV is generally considered to have targeted effects, high doses or systemic administration could potentially lead to wider immune modulation or other systemic effects that are not yet fully characterized.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Warnings for KPV largely stem from its status as a research compound with limited human data:
* **Lack of human safety data:** There is no extensive safety profile for KPV in humans. Its long-term effects, potential for accumulation, or interactions with human physiological systems are not fully understood.
* **Purity and quality concerns:** As KPV is not an FDA-approved drug, the purity, potency, and quality of commercially available research-grade KPV may vary significantly. Impurities could lead to unexpected effects or adverse reactions.
* **Immunogenicity:** Like other peptides, there is a theoretical risk that the body could develop an immune response against KPV itself, potentially reducing its effectiveness or leading to allergic reactions.
* **Use in specific populations:** Pregnant or breastfeeding individuals, children, and those with pre-existing medical conditions should avoid KPV due to the lack of safety data in these vulnerable populations.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Without comprehensive human clinical data, specific contraindications for KPV are not fully established. However, based on general principles for research compounds and immunomodulatory agents, it is prudent to consider the following as potential contraindications:
* **Hypersensitivity:** Individuals with known or suspected hypersensitivity to peptides or any components of KPV formulations.
* **Autoimmune diseases:** While KPV is studied for immunomodulation, its precise effects on the complex immune system of individuals with pre-existing autoimmune conditions are not fully known and could theoretically exacerbate or alter disease progression.
* **Immunosuppression:** Individuals who are severely immunosuppressed, such as organ transplant recipients or those undergoing chemotherapy, should likely avoid KPV, as its impact on a compromised immune system is unpredictable.
* **Active infections:** The impact of KPV on host response to active bacterial, viral, or fungal infections is not well-characterized, and its use might theoretically interfere with effective immune clearance.
* **Pregnancy and Lactation:** Due to the absence of safety data in pregnant or breastfeeding women, KPV should be avoided in these populations.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Information regarding specific drug-drug interactions with KPV is not available due to its status as a research compound. However, as an immunomodulatory peptide, caution should be exercised when considering its use with other agents that affect the immune system or inflammatory pathways:
* **Immunosuppressants:** Co-administration with immunosuppressive drugs (e.g., corticosteroids, calcineurin inhibitors) could theoretically result in altered efficacy of either KPV or the immunosuppressant, or lead to excessive immune suppression that increases infection risk.
* **Immunostimulants:** Combining KPV with immunostimulants could lead to unpredictable immune responses, as KPV itself modulates immune function.
* **Anti-inflammatory drugs:** While KPV has anti-inflammatory properties, combining it with conventional NSAIDs or other anti-inflammatory agents without clinical guidance could lead to additive effects or unforeseen interactions. Users should be cautious of potential cumulative effects on inflammatory pathways.
Given the lack of dedicated interaction studies, it is crucial to assume potential unknown interactions with any concurrently used medications, supplements, or other compounds.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
KPV can be administered at any time in a research setting, and there are no specific requirements related to food intake (either with or without food). Given its relatively short half-life of approximately 1 hour, maintaining consistent levels in research protocols might necessitate frequent administration, depending on the desired duration of action and the specific experimental design. The method, frequency, and dosage are user-directed and must be set by a licensed clinician or researcher for therapeutic applications.
Source for this section: Sources for When should you take KPV?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with KPV?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about KPV
KPV is a research peptide. It is also known as Lysine-Proline-Valine. What follows is drawn from peer-reviewed literature indexed on PubMed, FDA label text where a label exists, and NIH reference records.
KPV is commonly discussed in the context of supporting recovery. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For KPV, it is typically administered by injection and it is typically taken null. Always follow the specific dose your clinician or the product label prescribes.
KPV carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
KPV is a peptide, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers KPV with no sign-up.
Combining a peptide like KPV with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against KPV: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for KPV varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of KPV depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like KPV the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 90474670(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/90474670
Verify at
Publisher search links for KPV. These are places to check the information — they are not citations, so they are not numbered.
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on KPV?
Plain-text summary, safe to quote verbatim:
KPV, or Lysine-Proline-Valine, is a naturally occurring tri-peptide derived from the alpha-melanocyte-stimulating hormone (alpha-MSH). It is a synthetic analog of the C-terminal amino acid sequence of alpha-MSH, which is known for its immunomodulatory and anti-inflammatory effects. Research on KPV focuses on tissue recovery.
Source: DoseRoutine — https://doseroutine.com/library/kpv
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). KPV — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/kpv
What compounds are similar to KPV?
Others in the peptide category or studied for the same goals.
Which goals is KPV used for?
Other compounds studied for the same benefits as KPV.
Continue exploring
See every compound DoseRoutine catalogs for these goals.